Ozempic and Semaglutide: the UK Facts You Need

Step 1: Understand what semaglutide actually does in the body

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone called GLP-1 (glucagon-like peptide-1) that is released naturally after eating. By activating GLP-1 receptors, semaglutide signals the brain that the body has had enough food, slows the rate at which the stomach empties, and helps regulate blood sugar. Those two effects, appetite suppression and slower gastric emptying, are what underpin both its diabetes management role and, at higher doses, its effect on body weight.

The NHS medicines page for semaglutide covers both Ozempic and Wegovy, which can make the name confusion worse. Both entries sit under the same active ingredient, but the licensed indications differ. Getting clear on the mechanism first helps make sense of why dose and brand matter so much.

For a more detailed look at how the GLP-1 pathway drives weight change, the semaglutide mechanism of action page goes into the biology without the jargon.

Step 2: Match the brand to the licence it actually holds in the UK

Ozempic comes in 0.5mg, 1mg and 2mg injection pens, titrated under a diabetes prescriber's supervision. Its UK licence is type 2 diabetes. Wegovy's maintenance dose for weight management is 2.4mg weekly, with a newer 7.2mg single-dose pen approved by the MHRA in April 2026 for adults with obesity. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at the 2.4mg dose in adults with obesity and no diabetes.

That headline number is why Ozempic began appearing in weight-loss conversations: the active ingredient is the same, so people assumed the products were interchangeable. They are not. The dose is different, the regulatory approval is different, and a prescriber who issues Ozempic for weight loss would be doing so outside its licensed indication, with different governance and liability implications.

If you want to understand where Wegovy and Ozempic diverge in practical terms, the Wegovy and Ozempic comparison page lays out the specifics clearly.

Step 3: Know which medicines are actually licensed for weight loss in the UK right now

Two injectable GLP-1-based medicines hold UK licences for weight management in adults: Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Mounjaro is a dual GIP and GLP-1 receptor agonist, the only dual-agonist currently licensed for this use in the UK. In the SURMOUNT-5 head-to-head trial, published in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks.

Neither Ozempic nor Rybelsus (the oral semaglutide tablet licensed for type 2 diabetes) sits in the weight-management lane. A Wegovy tablet, also oral semaglutide but at weight-management doses, received MHRA approval in June 2026, the first oral GLP-1 medicine licensed for weight management in the UK. That is a separate product from Rybelsus. The full semaglutide overview covers all four semaglutide products and their respective licences in one place.

For adults weighing up whether semaglutide-based treatment is realistic for them, the semaglutide for weight loss page explains the eligibility criteria and what clinical assessment involves. Context on treatment costs is on the Wegovy pricing page, which covers what a legitimate private prescription includes.

Step 4: If you want weight-management treatment, here is the regulated route

Wegovy and Mounjaro are prescription-only medicines. The only legal route to them is a prescription issued after a clinical assessment by a qualified prescriber. On the NHS, Wegovy is available through specialist weight-management services; NICE's guidance on semaglutide for obesity (TA875) sets the eligibility criteria, and waiting lists vary. Mounjaro is entering NHS primary care on a phased basis from 2025 onwards, with criteria tightening around BMI and existing conditions.

Private routes exist for people who do not meet NHS criteria, prefer not to wait, or live outside an area where NHS access is currently active. The important thing is that whichever route you use, the pharmacy should be registered with the GPhC, you can check any UK online pharmacy on the GPhC register. Sellers offering semaglutide products without a prescription from an assessed prescriber are operating outside the law, and the MHRA has repeatedly warned that counterfeit weight-loss pens carry real risk of harm.

If you'd like to explore whether you're eligible for licensed weight-management treatment through a GPhC-registered pharmacy, the free consultation is the first step. Our prescribers, not software, read every submission the same day.